RIVAROXABAN | A208555 | LUPIN LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2025-03-20 | Terminated 2025-12-09 | — | |
| D. Del. | 2021-03-01 | Terminated 2026-01-28 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.7967
per ea
Lowest NADAC/Unit
$0.7967
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68180070906RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
| 68180070909RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.